European Pharmaceutical Review

AUGUST 9, 2022

The M&A data for the second quarter of 2022 shows that while both the number of pharma deals signed and their overall value are still low compared to 2021, there are signs of a revival. In addition, and quite significantly, it was “Big Pharma” that was largely responsible for this uptick.

Pharma 69

Pharma Biopharma Leads Specialization 69

Pharmaceutical Technology

MARCH 22, 2023

The appeal of process intensification continues to grow in the biopharma industry as a means of not only increasing the productivity, but also improving sustainability. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield.

Biopharma 52

Biopharma Manufacturing Engineering Specialization 52

PM360

JUNE 30, 2022

Inizio Advisory: This unit helps pharma, biotech, and life sciences companies to develop, execute, and operationalize their strategies across portfolio licensing and development, new product launches, established product and franchise strategy, HEOR, pricing, and market access. Inizio launches with five specialist business units: 1.

Specialization 97

Specialization Medical Healthcare Healthcare 97

European Pharmaceutical Review

FEBRUARY 21, 2023

How do you see the evolution of cannabis-based medicines, particularly when it comes to the ‘specials’ or fully licensed drug routes? For instance, GW Pharma has shown the potential for licensed cannabinoid drugs, building a $7 billion business based around Epidiolex (CBD oil with a small patient population for childhood epilepsy).

Medicine 132

Medicine Manufacturing Specialization Pharmaceutical 132

European Pharmaceutical Review

OCTOBER 2, 2023

CPHI Barcelona, the renowned global pharma event, is set to take centre stage from 24 to 26 October 2023 at Fira Barcelona Gran Via, Spain. CPHI creates connections and inspires partnerships across the global pharma community. CPHI creates connections and inspires partnerships across the global pharma community.

Manufacturing 105

Manufacturing Pharma Networking Engineering 105

pharmaphorum

JANUARY 10, 2023

As two in five pharma leaders say that moving to a consumer-first mindset is a priority for the next two years, digital customer experience agency Graphite Digital is to publish a special edition of its Contradiction Conundrum whitepaper report, released in partnership with Reuters Events Pharma last year.

Pharma 52

Pharma Specialization Sales Biopharma 52

Pharmaceutical Technology

JUNE 15, 2023

AI in pharma R&D is one of the latest innovations helping teams apply existing knowledge to new problems. Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. Here are a few ways AI is used in pharma today.

Pharma 52

Pharma Management Networking Manufacturing 52

Pharmaceutical Technology

OCTOBER 3, 2022

Myovant Sciences has rejected an acquisition offer worth $2.5bn from Sumitovant Biopharma and its wholly-owned subsidiary Sumitomo Pharma, citing it 'significantly undervalues' the company. for each share in cash. At present, Sumitovant owns nearly 52% of Myovant’s outstanding shares.

Food and Drug Administration 52

Food and Drug Administration Specialization Biopharma Food 52

Eversana Intouch

FEBRUARY 23, 2023

Let’s talk about the current economic uncertainty and what it means for pharma marketers. Biopharma valuations are down, especially for public and earlier-stage companies. Talent shortages continue, particularly in executive and specialized R&D roles, while simultaneously layoffs , especially in biotech, are on the rise.

Marketing 52

Marketing Pharma Patients Insurance 52

Eversana Intouch

FEBRUARY 23, 2023

Let’s talk about the current economic uncertainty and what it means for pharma marketers. Biopharma valuations are down, especially for public and earlier-stage companies. Talent shortages continue, particularly in executive and specialized R&D roles, while simultaneously layoffs , especially in biotech, are on the rise.

Marketing 52

Marketing Pharma Patients Insurance 52

Pharmaceutical Technology

MAY 24, 2023

Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. CGT have highly unique and specialized manufacturing processes. This is a primary factor for the staggeringly high unit cost of CGT.

Manufacturing 98

Manufacturing Transportation Specialization Patients 98

Clarivate

NOVEMBER 17, 2021

Carolyn Hynes: I think of regulatory intelligence (RI) as a very specialized role within the regulatory affairs function. We’ve also released a complimentary report on this podcast topic, Showing the value of regulatory intelligence in pharma. Mike Ward: Carolyn and Celine, thanks very much for joining me.

Pharma 52

Pharma Healthcare Healthcare Specialization 52

PM360

NOVEMBER 21, 2022

Those in the biopharma industry can play a pivotal role in shortening the journey to diagnosis if they learn from patients what critical pieces had to fall into place before they were diagnosed. It’s also in these communities where biopharma finds the best opportunities to connect with their stakeholders.

Patients 52

Patients Medicine Biopharma Media 52

The Marketing Advantage

APRIL 6, 2021

April 6, 2021 The biopharma industry rightfully places a great deal of emphasis on the importance of having a sales compensation plan that pays for performance. In order to truly pay for performance, a biopharma sales compensation plan must be designed such that it meets the following two attributes: Pay-for-Performance Attributes.

Sales 52

Sales Biopharma Marketing Specialization 52

PM360

JUNE 24, 2024

A form of artificial intelligence (AI) specialized in voice cloning used Travis’ voice, as recorded over a decades-long career, to fill in the vocals of the song. Yet from a risk-mitigation perspective, we anticipate a cautious, measured approach by most biopharma companies. In the patient engagement space, the potential is immense.

Healthcare 52

Healthcare Healthcare Patients Side effects 52

Pharmaceutical Technology

JANUARY 25, 2023

Although expert opinions differ on the future of special purpose acquisition companies (SPACs), some companies are continuing to explore their use. In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. trillion of dealmaking firepower.

Marketing 69

Marketing Biopharma Pharma Competition 69

PM360

SEPTEMBER 15, 2022

Empathy needs to be a core strategic imperative for pharma brands. In order to improve patient inclusivity in clinical trials, the biopharma industry must incorporate DEI in all processes. This is a tangible human challenge. It becomes a connector between the human and digital worlds with regard to patient care and support.

Patients 98

Patients Healthcare Healthcare Marketing 98

PM360

JUNE 11, 2022

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. Patients want to know other patients are involved in what pharma is doing. Learn how pharma is involving them. They want to hear about those patients’ experiences.

Patients 59

Patients Pharma Education Media 59

Clarivate

MAY 24, 2023

With gene therapies, like any specialized treatment, payers are going to be very stringent in making sure patients meet the criteria for treatment, given the cost they’re carrying,” said Kiernan. Payers are also eyeing a variety of stringent utilization management measures to prevent unnecessary care and rein in costs.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Clarivate

MAY 24, 2022

Multinational pharmas seek entry for their products. Multinational pharmas have taken notice of the recent policy focus of Mainland China’s healthcare authorities on rare diseases. China’s rapidly evolving and increasingly dynamic rare disease market provides pharmas an opportunity for strong growth.

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

Pharma Marketing Network

JANUARY 12, 2023

In three short years, Kite has grown to be the largest CAR T-cell therapy company in the world, with an extensive in-house manufacturing network devoted to creating this specialized treatment for patients. In addition to serving as an advocate for patients, Christi has been a role model and mentor for women throughout her career.

Healthcare 52

Healthcare Healthcare Networking Manufacturing 52

MedCity News

JUNE 16, 2023

Numerous clinical, regulatory and financial factors are behind this digital shift in pharma.

Pharma 311

Pharma Food and Drug Administration Recruitment Patients 311

Pharmaceutical Technology

MARCH 20, 2023

Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials.

Distribution 52

Distribution Management Patients Transportation 52

PM360

AUGUST 7, 2024

Christoph Bug Vice President of Global Medical Veeva christoph.bug@veeva.com Functional silos can create tunnel vision and cause misalignment of strategy, objectives, and transparency of interactions with biopharmas and their customers like HCPs. To best align success measures and unify systems (and people) start with the end goal in mind.

Media 52

Media Education Physicians Marketing 52

PM360

OCTOBER 3, 2023

PRODUCT LAUNCH OF THE YEAR NEXTSTELLIS (Mayne Pharma and EVERSANA INTOUCH) RELAUNCH/REVITALIZATION OF THE YEAR VRAYLAR (AbbVie Inc. Director, Obesity Market Access Strategy, Novo Nordisk Medical Device/Diagnostics: Brett Sarnoff, Vice President of Marketing Medical Device & Pharma Systems, North America, B. Braun Medical, Inc.

Marketing 122

Marketing Education Media Pharmaceutical 122

PM360

AUGUST 24, 2023

Now, Real Chemistry is at the forefront of applying analytics, data, and artificial intelligence to the biopharma and healthcare industry and, in 2022, the company achieved its 21st consecutive year of double-digit growth. Brett Sarnoff, Vice President of Marketing Medical Device & Pharma Systems, North America, B.

Marketing 52

Marketing Pharmaceutical Healthcare Healthcare 52

PM360

OCTOBER 5, 2023

Now, Real Chemistry is at the forefront of applying analytics, data, and artificial intelligence to the biopharma and healthcare industry and, in 2022, the company achieved its 21st consecutive year of double-digit growth. Weiss has also made substantial efforts to give back to the community at large. Braun Medical, Inc.

Marketing 52

Marketing Education Pharmaceutical Media 52

Pharmaceutical Technology

APRIL 24, 2023

Because biologics work with live cells, manufacturing them is difficult, and highly specialized facilities and infrastructure are needed. Free Whitepaper Choosing the ‘right’ CRO/CDMO in Biopharma: What has changed? Biopharma outsourcing has rapidly developed.

Manufacturing 52

Manufacturing Food and Drug Administration Biopharma Sales 52

Pharmaceutical Technology

OCTOBER 27, 2022

This could have wide-reaching effects on emerging pharmaceutical markets such as China, which are seeking to acquire innovative pharma manufacturing expertise in the US. Last month, F-star Therapeutics (Cambridge, UK) disclosed that a CFIUS national security review of its sale to Sino-Biopharma (Hong Kong) had moved into an extended review.

Manufacturing 106

Manufacturing Biopharma Government Pharma 106

MedCity News

NOVEMBER 7, 2024

Avid specializes in manufacturing biologic products for companies at all stages of development. CDMO Avid Bioservices is being acquired by the private equity firms GHO Capital Partners and Ampersand Capital Partners. The post Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition appeared first on MedCity News.

Specialization 299

Specialization Manufacturing Biopharma Pharma 299

Pharmaceutical Technology

AUGUST 26, 2008

“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. ”

Pharmaceutical 40

Pharmaceutical Manufacturing Biopharma Medicine 40